← All institutions

Goldman Sachs

365 reports

Reports from this institution

Goldman Sachs

Goldman Sachs: Large models accelerate robot deployment, but precision control and real-world data remain hurdles

Frontier models are improving robots’ ability to adapt to new tasks, but high-precision perception, real-time control and data collection continue to constrain commercialization. Goldman Sachs believes robots’ competitive advantages will increasingly shift toward hardware-software integration, with upstream sensing and data collection potentially benefiting earlier.

Goldman Sachs

Goldman Sachs: High-end copper-clad laminates drive better-than-expected profits; Goldman Sachs backs expansion and price increases at two Taiwanese manufacturers

Elite Material and Taiwan Union Technology reported third-quarter core operating profits 6% and 16% above Goldman Sachs’ expectations, respectively. Goldman expects product upgrades and price increases to lift both companies’ fourth-quarter gross margins to about 41%, though their capacity rollout schedules and customer project transitions differ.

Goldman Sachs

Goldman Sachs: Gan & Lee Pharmaceuticals' third-quarter results miss expectations: Overseas licensing revenue delayed, while innovative drug progress supports growth outlook

Third-quarter revenue rose 16.9% year on year, but Goldman Sachs said a delay in recognizing business development and licensing revenue weighed on results. Overseas sales and two innovative drug candidates made progress, while potentially higher R&D spending prompted Goldman Sachs to lower its earnings forecasts for the next two years.